Pharmacotherapy Considerations in Hospitalized Patients With COVID-19 Pneumonia

William Pruett, MD; Lee E. Morrow, MD, MSc, FCP, FCCP, FCCM, ATSF; Mark A. Malesker, PharmD, FCCP, FCCP, FCCM, FASHP, BCPS


US Pharmacist. 2020;45(44020):HS9-HS16. 

In This Article


Data regarding COVID-19 are evolving so quickly that much of the information in this review is anecdotal, and some of it is likely obsolete already. However, COVID-19 has imparted a host of lessons, many of which are not specific to this novel coronavirus and therefore provide opportunities to prepare for future pandemics. A definitive treatment algorithm for COVID-19 therapy will remain elusive so long as disagreement abounds—and disagreement is inevitable when objective data are lacking. Although FDA approval is being sought for a number of COVID-19–specific agents, the bulk of COVID-19 treatment is meticulous, evidence-based, and supportive. However, supportive therapies must be provided optimally, which is a challenging task when key drugs are unavailable, multiorgan failure is common, and nonintensivist physicians are caring for critically ill patients because of staffing limitations. Therefore, the clinical pharmacist must commit to the twin roles of educator and enforcer when assisting in the care of COVID-19 patients.